Psychopharmacology

From the impact of patients’ overdose deaths on physicians to addressing America’s mental health crisis, here are highlights from the week in Psychiatric Times.

"The history of medicine is rich in blaming the disease or the patient for 'untreatable' symptoms, until we stumble upon or develop a treatment that is, in fact, effective."

The experts weighed in on a wide variety of psychiatric issues for the January 2023 issue of Psychiatric Times.

From a new FDA approval to treating “New Year depression” in patients, here are highlights from the week in Psychiatric Times.

Data on the effects of discontinuing lithium on renal function are scarce and conflicting. A new study exploring these effects may aid in the clinical decision-making process.

We remain challenged to improve treatments and outcomes in schizophrenia. Explore the latest options.

The experts weighed in on a wide variety of psychiatric issues for the December 2022 issue of Psychiatric Times.

From current treatments for cannabis use disorder to new possibilities for the treatment of dementia, here are highlights from the week in Psychiatric Times.

From new legislation that would expand the US approach to mental health to drug abuse trends and treatment approaches for 2023, here are highlights from the week in Psychiatric Times.

Check out the best clinical pearls from the 2022 Neuroscience Education Institute (NEI) Congress!

From an in-depth analysis of ADHD in clinical practice to differences in effectiveness between intravenous and intranasal ketamine, here are highlights from the week in Psychiatric Times.

This latest submission completes the FDA filing that was initiated in May.

Does route of administration affect antidepressant efficacy of ketamine? Researchers performed a meta-analysis of trials comparing intravenous and intranasal administration.

The drug is in development for the treatment of acute depressive disorders and depression with suicidality.

The experts weighed in on a wide variety of psychiatric issues for the November 2022 issue of Psychiatric Times.

In this CME article, learn how to apply novel treatment approaches for patients with bipolar depression.

From the unique challenges of treating physician-patients to updates on MDMA and psilocybin research and access, here are highlights from the week in Psychiatric Times.

An important adverse effect of SRIs: their association with increased bleeding.

Understanding and addressing the unmet therapeutic needs of individuals living with mental health conditions.

From the cardiac adverse effects of lithium to the road to over-the-counter naloxone, here are highlights from the week in Psychiatric Times.

What is the buzz about the power of artificial intelligence?

When should you monitor electrocardiograms in patients taking lithium?

In the case of antidepressants, a few recent articles may make it tempting to throw the baby out with the bathwater. But on close examination, that would be a mistake on many levels...

From the relationship between psychotic disorders and dementia risk to the major differences between bipolar I and bipolar II, here are highlights from the week in Psychiatric Times.

The experts weighed in on a wide variety of psychiatric issues for the October 2022 issue of Psychiatric Times.

What are the elements of a good meta-analysis?

What is the effect of cannabis use on adherence to medications in patients with psychosis?

From the at-home ketamine experience to the Wit v United Behavioral Health reversal, here are highlights from the week in Psychiatric Times.

"As clinicians who took an oath to 'do no harm,' we must educate the public about the dangers and non–standard of care of the growing practice of at-home ketamine."